SinglePoint, Inc. (OTC: SING), a publicly traded holding company, offers just such non-traditional upside opportunity with its foray into the burgeoning cannabis market.
SinglePoint, Inc. (OTC: SING), a publicly traded holding company, offers just such non-traditional upside opportunity with its foray into the burgeoning cannabis market.
The upward trajectory of the cannabis industry has garnered comparisons to the Internet boom of the early 2000s, as North American sales are on pace to record a compound annual growth rate of 25 percent through 2021, according to Arcview Market Research (1).
ChineseInvestors.com, Inc. (OTCQB: CIIX) is launching a line of hemp-infused skin care products in China. The cannabinoid content of the line makes these products more than just cosmetics.
India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions.
As more countries begin to allow some form legalization, opportunities arise for Canadian companies to expand their business. It’s hard to ignore the fact that the boom of Canadian stocks as the country prepares for legal recreational cannabis use has been felt on a global scale.
Currently, India Globalization Capital (IGC) is the only publicly traded pharmaceutical cannabis stock that addresses Alzheimer’s disease, which positions the company with a first-mover advantage in phytocannabinoid-based combination therapy.
Diamond CBD Sales, a subsidiary of PotNetwork Holding, Inc. (OTC: POTN), attained more than $200,000 in sales at the Big Industry Trade Show in New York on August 10-11.
Before the opening bell, Singlepoint, Inc. (OTC: SING) kicked off the new year by voicing its support for an ongoing congressional push calling for banking reform as it relates to the burgeoning legal cannabis industry.
Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon.
Pot is what alcohol used to be. It’s an industry ready to take off, but one that’s still finding its way , and one whose progress is not exactly encouraged by the federal government. It’s a little bit like Prohibition 2.0.
CanniMed Therapeutics Inc. (TSX:CMED)today released its financial results for the three and nine months ended July 31, 2017. Highlights Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product.
Medical marijuana has among the highest values in the broader marijuana space, and as with any burgeoning industry, savvy investors are looking for evidence of the market’s core value.
Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available.